Milan, Italy – September 3, 2009 – Newron Pharmaceuticals SpA, a research and development company focused on novel CNS and pain therapies, announced today that positive results of a preclinical study of ralfinamide in an experimental model of central pain will be presented at the Sixth International Congress of the European Federation of IASP Chapters (EFIC), Lisbon, Portugal, September 9-12, 2009.
The study was conducted by Professor Ze’ev Seltzer, Senior Canada Research Chair in Genetics of Pain, University of Toronto, Canada. The poster entitled “Oral ralfinamide suppresses autotomy following hindpaw deafferentation by multiple dorsal rhizotomies, a rat model of CNS-mediated spontaneous neuropathic pain” will be presented during the Poster Session on Thursday, September 10, 2009, 16:00-16:45, abstract n. 314.
About Ralfinamide
Ralfinamide is a unique new chemical entity that is believed to mediate its potent analgesic effect through the inhibition of sodium channels, including Nav 1.7, N-type Calcium channels and NMDA receptor. It is currently in Phase IIb/III for Neuropathic Low Back Pain.
About Newron Pharmaceuticals
Newron Pharmaceuticals S.p.A. (www.newron.com) is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System and pain. Newron is undertaking phase III trials with safinamide for the treatment of Parkinson’s disease (PD) in conjunction with its partner, Merck Serono, which has exclusive worldwide rights to develop, manufacture and commercialize the compound in PD, Alzheimer’s disease, and other therapeutic applications. Newron recently initiated SERENA, a potentially pivotal study with ralfinamide in patients with neuropathic low back pain (NLBP). There are no approved drugs for the treatment of NLBP, an indication experienced by about 55 million patients in the USA, Europe and Japan. Newron is headquartered in Bresso, near Milan, Italy. The company is listed at SIX Swiss Exchange, trading symbol NWRN.
Important Notices
This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates and current and future collaborations for the development and commercialisation of its product candidates and reduce costs (including staff costs), (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s anticipated future revenues, capital expenditures and financial resources, and (4) assumptions underlying any such statements. In some cases these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron’s strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements.
By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions.
Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron’s research programmes, development activities, commercialisation plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions.
Newron does not undertake any obligation to publicly up-date or revise forward looking statements except as may be required by applicable regulations of the SIX Swiss Exchange where the shares of Newron are listed.
This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.
